Wellbutrin, Zyban (bupropion) dosing, indications, interactions, adverse effects, and more. Contraindications. Hypersensitivity to bupropion or other ingredients. History of anorexia/bulimia; patients undergoing abrupt discontinuation of ethanol or sedatives including anticonvulsants, barbiturates, or benzodiazepines. Coadministration of any other medications that contain bupropion, because seizures are dose dependent. Aplenzin contraindications. Seizure disorder or conditions that increase seizure risk (arteriovenous malformation, severe head injury, CNS tumor, CNS infection, severe stroke, anorexia nervosa or bulimia (current or prior diagnosis)Coadministration with MAOIs. Coadministration may cause serotonin syndrome. Do not use concomitantly or initiate bupropion within 1. MAOIConversely, at least 1. MAOI antidepressant. Starting bupropion in a patient who is being treated with linezolid or IV methylene blue is contraindicated because of an increased risk of serotonin syndrome. If linezolid or IV methylene blue must be administered, discontinue bupropion immediately and monitor for CNS toxicity; may resume 2.
Cautions. Caution in severe hepatic cirrhosis (do not exceed 1. CNS tumor, concomitant meds lowering seizure threshold. Observe patients for neuropsychiatric symptoms, such as changes in behavior, hostility, agitation, depressed mood, and suicide- related events, including ideation, behavior, and attempted suicide (see Black Box Warnings); therapy may cause delusions, hallucinations, psychosis, paranoia, confusion, and concentration disturbance; symptoms may abate with dose reduction. Potential risk of hepatotoxicity. Assess blood pressure before initiating treatment with sustained release formulation, and monitor periodically during treatment; risk of hypertension is increased if sustained release formulation is used concomitantly with MAOIs or other drugs that increase dopaminergic or noradrenergic activity; use caution in patients with cardiovascular disease. May cause weight loss; use caution if weight loss not desirable. May cause CNS depression and impair ability to operate heavy machinery. Extended- release: Do not administer less than 8 hr apart Seizure risk is dose- related; can minimize risk by limiting daily dose to 5. May cause sexual dysfunction. Screen patients for bipolar disorder and. Instruct patients to contact. Perform thorough cardiovascular assessment to identify risk factors of sudden cardiac death in pediatric ADHD patients. Risk of mydriasis; may trigger angle closure attack in patients with angle closure glaucoma with anatomically narrow angles without a patent iridectomy; use caution. False- positive urine immunoassay screening tests for amphetamines have been reported; confirmatory test (eg, gas chromatography, mass spectrometry) will distinguish bupropion from amphetamines. Bupropion hydrobromide extended- release tablets are intended for oral use only; inhalation of crushed tablets or injection of dissolved bupropion reported; seizures and/or cases of death reported when administered intranasally or by parenteral injection. Abuse warning. XL and SR tablets are intended for oral use only. Inhaling crushed tablets or injecting dissolved tablets has been reported to cause seizures and/or death. Bupropion (Wellbutrin) Brand Names: Wellbutrin ®, Wellbutrin SR ®, Wellbutrin XL ®, Zyban ®, Budeprion SR ®, Budeprion XL ®, Aplenzin TM and Buproban®. Physician-supervised Weight-loss (Overweight, Obesity and Severe Obesity) Physician-supervised weight-loss programs provide treatment in a clinical setting with a.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. Archives
August 2017
Categories |